Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке: https://scidar.kg.ac.rs/handle/123456789/13987
Пун извештај метаподатака
Поље DC-а ВредностЈезик
dc.rights.licenseopenAccess-
dc.contributor.authorTesic, Milorad-
dc.contributor.authorBeleslin B.-
dc.contributor.authorGiga V.-
dc.contributor.authorJovanovic, Ivana-
dc.contributor.authorMarinkovic J.-
dc.contributor.authorZamaklar-Trifunović D.-
dc.contributor.authorPetrovic O.-
dc.contributor.authorDobric M.-
dc.contributor.authorAleksandrić S.-
dc.contributor.authorJuricic S.-
dc.contributor.authorBošković N.-
dc.contributor.authorTomasević M.-
dc.contributor.authorRistić Fira A.-
dc.contributor.authorOrlic D.-
dc.contributor.authorStojković A.-
dc.contributor.authorVukcevic V.-
dc.contributor.authorStankovic, Goran-
dc.contributor.authorOstojic M.-
dc.contributor.authorDjordjević-Dikić A.-
dc.date.accessioned2022-02-02T17:44:35Z-
dc.date.available2022-02-02T17:44:35Z-
dc.date.issued2021-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/13987-
dc.description.abstractBACKGROUND: Microvascular dysfunction might be a major determinant of clinical deterioration and outcome in patients with hypertrophic cardiomyopathy (HCM). However, long-term prognostic value of transthoracic Doppler echocardiography (TDE) coronary flow velocity reserve (CFVR) on clinical outcome is uncertain in HCM patients. Therefore, the aim of our study was to assess long-term prognostic value of CFVR on clinical outcome in HCM population. METHODS AND RESULTS: We prospectively included 150 HCM patients (82 women; mean age 48±15 years). Patients’ clinical characteristics, echocardiographic and CFVR findings (both for left anterior descending [LAD] and posterior descending artery [PD]), were assessed in all patients. The primary outcome was a composite of: HCM related death, heart failure requir-ing hospitalization, sustained ventricular tachycardia and ischemic stroke. Patients were stratified into 2 subgroups depend-ing on CFVR LAD value: Group 1 (CFVR LAD>2, [n=87]) and Group 2 (CFVR LAD≤2, [n=63]). During a median follow-up of 88 months, 41/150 (27.3%) patients had adverse cardiac events. In Group 1, there were 8/87 (9.2%), whereas in Group 2 there were 33/63 (52.4%, P<0.001 vs. Group 1) adverse cardiac events. By Kaplan-Meier analysis, patients with preserved CFVR LAD had significantly higher cumulative event-free survival rate compared to patients with impaired CFVR LAD (96.4% and 90.9% versus 66.9% and 40.0%, at 5 and 8 years, respectively: log-rank 37.2, P<0.001). Multivariable analysis identified only CFVR LAD≤2 as an independent predictor for adverse cardiac outcome (HR 6.54; 95% CI 2.83–16.30, P<0.001), while CFVR PD was not significantly associated with outcome. CONCLUSIONS: In patients with HCM, impaired CFVR LAD (≤2) is a strong, independent predictor of adverse cardiac outcome. When the aim of testing is HCM risk stratification and CFVR LAD data are available, the evaluation of CFVR PD is redundant.-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.sourceJournal of the American Heart Association-
dc.titlePrognostic value of transthoracic doppler echocardiography coronary flow velocity reserve in patients with asymmetric hypertrophic cardiomyopathy-
dc.typearticle-
dc.identifier.doi10.1161/JAHA.120.021936-
dc.identifier.scopus2-s2.0-85119303739-
Налази се у колекцијама:Faculty of Medical Sciences, Kragujevac

Број прегледа

854

Број преузимања

33

Датотеке у овој ставци:
Датотека Опис ВеличинаФормат 
10.1161-JAHA.120.021936.pdf587.41 kBAdobe PDFСличица
Погледајте


Ова ставка је заштићена лиценцом Креативне заједнице Creative Commons